Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

Sattva S. Neelapu, Sherry Adkins, Stephen M. Ansell, Joshua Brody, Mitchell S. Cairo, Jonathan W. Friedberg, Justin P. Kline, Ronald Levy, David L. Porter, Koen Van Besien, Michael Werner, Michael R. Bishop

Research output: Contribution to journalReview articlepeer-review


The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.

Original languageEnglish (US)
Article numbere001235
JournalJournal for ImmunoTherapy of Cancer
Issue number2
StatePublished - Dec 24 2020


  • antineoplastic protocols
  • guidelines as topic
  • hematologic neoplasms
  • immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma'. Together they form a unique fingerprint.

Cite this